Previous Article | Next Article ![]()
J Bacteriol, July 1998, p. 3556-3562, Vol. 180, No. 14
Department of Microbiology and Immunology,
University of British Columbia, Vancouver, British Columbia, Canada
V6T 1W5
Received 14 January 1998/Accepted 5 May 1998
OprF, the major outer membrane protein of Pseudomonas
aeruginosa, is multifunctional in that it can act as a
nonspecific porin, plays a role in the maintenance of cell shape, and
is required for growth in a low-osmolarity environment. The latter two
structural roles of OprF, and OprF's association with the
peptidoglycan, have been proposed to be localized in the carboxy
terminus of the protein, based on this region's similarity to members
of the OmpA family of proteins. To determine if this is correct, we
constructed a series of C-terminally truncated OprF derivatives
and examined their effects on P. aeruginosa cell
length and growth in low-osmolarity medium. While the C
terminus of OprF was required for wild-type cell length and growth in
low-osmolarity medium, expression of the N terminus
(first 163 amino acids [aa]) also influenced these phenotypes
(compared with OprF deficiency). The first 154 to 164 aa of OprF
seemed required for stable protein expression, consistent with the
existence of a Pseudomonas aeruginosa is
an opportunistic pathogen that can cause severe infections in
cystic fibrosis patients, burn victims, and patients with a
weakened immune system (3). P. aeruginosa is of particular concern because of its intrinsic
resistance to antibiotics, a property due largely to the low
permeability of its outer membrane, coupled with other resistance
mechanisms such as periplasmic OprF is thought to be structurally similar to Escherichia
coli OmpA and other related members of the OmpA family of proteins (48). Its structure has been proposed to comprise three
domains: an N-terminal domain (first ~160 amino acids [aa])
containing eight antiparallel To further elucidate the structure of OprF and its relationship to
function, we have now constructed and characterized a series of
C-terminally truncated OprF derivatives. We have examined the effects
of truncating OprF on such phenotypes as cell shape and growth in
low-osmolarity medium and provide evidence consistent with the
existence of a Bacterial strains, plasmids and in vitro growth conditions.
P. aeruginosa H103 (PAO1 prototroph) is our wild-type
reference strain (17), and P. aeruginosa
H636 is an OprF-deficient mutant of P. aeruginosa H103
previously constructed by
0021-9193/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Roles of the Carboxy-Terminal Half of Pseudomonas
aeruginosa Major Outer Membrane Protein OprF in Cell Shape, Growth
in Low-Osmolarity Medium, and Peptidoglycan Association
![]()
ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
-barrel domain in the N terminus of OprF. Greater
than 215 aa of the protein were required for strong peptidoglycan association, confirming that residues in the C-terminal end of OprF are
required for peptidoglycan binding. OprF deficiency did not affect the
in vivo growth of an OprF-deficient strain in a mouse chamber model.
Collectively, these data suggest that the C terminus of OprF plays a
role in cell length, growth of P. aeruginosa in
low-osmolarity media (but not in vivo), and peptidoglycan association, while the N terminus has an influence on the first two characteristics and is additionally important for stable protein expression.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
-lactamase or efflux, which benefit
from the slow diffusion of such antibiotics into the cell (5,
27). Clinical isolates of P. aeruginosa which are
multiply antibiotic resistant and deficient in the major outer membrane
protein OprF have been obtained (6, 31). OprF has been shown
to function as a nonspecific porin (47). However, OprF seems
to be multifunctional since it is noncovalently linked to peptidoglycan
and involved in the maintenance of cell shape and growth in
low-osmolarity environments (15, 18, 26, 47).
sheets that are proposed to form a
-barrel structure; a loop or hinge region (161 to 209 aa) containing
a poly-proline-alanine repeat region and two disulfide bonds; and a
C-terminal domain (210 to 326 aa) which is highly conserved with the
corresponding domains of other OmpA family proteins. However,
controversy surrounds the proposed structure of OprF. Predictions for
the structure of the C-terminal domain have ranged from that of a
relatively globular domain which is located exclusively in the
periplasm (the most prevalent model for OmpA) to a domain containing a
significant proportion of anti-parallel
sheets that are associated
with the outer membrane (42, 44, 45). There is a need to
verify experimentally some of the theories regarding OprF structure,
particularly those based on sequence analysis and extrapolation of
studies of other OmpA family proteins. For example, it has been
proposed that the C-terminal domain of OprF may contain the residues
involved in peptidoglycan binding, since this region shows significant
sequence similarity with other proteins that are peptidoglycan
associated (9, 17); however, this has not yet been confirmed
experimentally. The N terminus of OprF is thought to form a
-barrel
structure similar to that proposed for the well-studied E. coli OmpA protein; however, this N-terminal region has no
significant sequence similarity to any known protein sequence,
including OmpA (with the exception of the equivalent region of OprF
found in other Pseudomonas species). Studies such as the
mapping of OprF surface epitopes and genetically inserted malarial
epitopes (23, 44) have been useful in proposing the topology
of this region; however, more experimental data are needed to support
these structural predictions for OprF. Our understanding of the
relationship between the structure of OprF and its function is also
still quite poor.
-barrel domain in the N terminus of OprF and of a
peptidoglycan-associated domain in the C terminus of the protein. A new
OprF-deficient strain was constructed to confirm the phenotypes
associated with OprF deficiency, and we also examined the growth of an
OprF-deficient P. aeruginosa strain in a mouse chamber
model to see if this strain had any growth disadvantage in vivo.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
mutagenesis (47).
P. aeruginosa M-2 is a mouse-pathogenic strain that was originally isolated from the gastrointestinal tract of normal mice
(40) and used as the parent strain for construction of a
second
-mutagenized OprF-deficient strain (M-2F
[this
work]). E. coli DH5
[F
80dlacZ
M15 endA1 recA1 hsdR17
(rK
mK+) supE44
thi-1 gyrA96 relA1
(lacZYA-argF)U169]
was used for all basic cloning experiments, and E. coli C441
[(pro r
m+)::RP4-2-Tc::Mu-Km::Tn7]
was the donor helper strain in biparental mating experiments for the
construction of M-2F
. The plasmids used in this study are
listed in Table 1. All medium components
were from Difco Laboratories (Detroit, Mich.). E. coli
strains were grown on Luria-Bertani medium (LB; 1% Bacto Tryptone,
0.5% yeast extract, 1% NaCl [pH 7.0]), and P. aeruginosa strains were grown on Mueller-Hinton medium or LB
high-salt medium (LBHS; 1% tryptone, 0.5% yeast extract, 200 mM NaCl
[pH 7.0]). The low-osmolarity medium used in growth experiments was
either PP2 (1% Protease Peptone no. 2) or salt-free LB (1% tryptone, 0.5% yeast extract [pH 7.0]). Media were solidified with 2% Bacto Agar. Antimicrobial agents were used at the following concentrations for E. coli: tetracycline at 25 µg/ml, ampicillin at 75 or
100 µg/ml, and kanamycin at 25 µg/ml. For P. aeruginosa, the following concentrations were used: tetracycline
at 200 µg/ml, kanamycin at 250 µg/ml, streptomycin at 500 µg/ml,
and carbenicillin at 300 µg/ml.
TABLE 1.
Plasmids used in this study
DNA procedures.
Most common DNA procedures were performed as
described by Sambrook et al. (34). Plasmid DNA was routinely
isolated by the alkaline lysis method of Birnboim and Doly
(2), with further purification by polyethylene glycol
precipitation when the DNA was to be used in sequencing reactions (as
described in the manual for the Taq DyeDeoxy terminator
cycle sequencing kit from Applied Biosystems Incorporated [ABI]). DNA
was sequenced with an ABI model 373A automated sequencing system as
instructed by the manufacturer, and oligonucleotides were synthesized
on an ABI model 392 DNA/RNA synthesizer as described by the
manufacturer. Electroporation of P. aeruginosa was done
as described by Farinha and Kropinski (10) except that
high-salt medium containing 50 mM MgCl2 was used for the
recovery period after electroporation. Biparental mating was performed
essentially as described by Goldberg and Ohman (14), and
P. aeruginosa M-2 was subjected to
mutagenesis exactly as described by Woodruff and Hancock (47). For the
construction of OprF truncation mutants by PCR, either Vent or
Taq DNA polymerase (Fisher Scientific) was used under
standard conditions suggested by the manufacturer. PCR was performed in
an MJ Research thermal cycler with the following thermal profile
repeated 30 times: 95°C for 15 s, 55°C for 30 s, and
72°C for 90 s.
Protein and immunological procedures. Outer membranes were prepared by the one-step sucrose gradient method of Hancock and Carey (17), and peptidoglycan-associated proteins were prepared by the method of Hancock et al. (18). A modified Lowry assay was used to determine protein concentrations (30). Proteins were prepared for electrophoresis by solubilization in 2% (wt/vol) sodium dodecyl sulfate (SDS) with or without the addition of 2% (wt/vol) 2-mercaptoethanol. Some samples prepared from whole-cell lysates were sonicated three times for 15 s in a sonicating water bath. All samples were heated to 100°C for 10 min immediately before electrophoresis. Heat-treated samples were boiled for a minimum of 30 min in SDS or treated with 5% (wt/vol) trichloroacetic acid (TCA) for 30 min on ice (17). Proteins were separated by electrophoresis in 11, 12, or 14% polyacrylamide gels as previously described (17). The gels were stained with Coomassie brilliant blue R250 (Bio-Rad) for visualization of proteins. OprF-specific monoclonal antibodies were described previously (25, 29, 32). Fast protein liquid chromatography-purified OprF was used to make the polyclonal rabbit and polyclonal mouse sera (32). Colony immunoblotting and Western immunoblotting were performed as described previously (24, 25).
Construction of truncated versions of OprF. All plasmids constructed in this study were based on pUCP19 and a HindIII/EcoRI insert containing a weakened oprF promoter and a portion of the oprF gene. The weakened oprF promoter permitted wild-type levels of expression of OprF from a multicopy plasmid (reference 44 and this work). Full-length OprF was encoded on plasmid pRW5 (Table 1).
The plasmids encoding truncated versions of OprF (Table 1) were constructed by using the following three basic approaches. First, a KpnI fragment, coding for aa 103 to 170 and 301 to 326 of OprF from pWW5 (47), was used to replace the wild-type KpnI fragment from pRW5, resulting in plasmid pER170-26 (the plasmid number refers to the remaining OprF amino acids, i.e. the N-terminal 170 and C-terminal 26 aa). In a similar manner, plasmid pER102 (encoding the N-terminal 102 aa) was constructed by deleting the 1.1-kb KpnI fragment coding for the C-terminal two-thirds of OprF from plasmid pRW5. The second approach involved inserting an adapter oligonucleotide, encoding stop codons in all three reading frames, into unique PstI sites present in a set of plasmids encoding linker insertion mutants of OprF (44). Plasmids constructed this way were designated pER188, pER213, pER215, and pER290. This method resulted in the addition of the following amino acids to the C terminus of the truncated protein: DNV (for pER188), VQLDVK (for pER213), LDV (for pER215), and VNAVGY (for pER290). As none of the linker mutants described above had insertions near the prospective hinge (proline-rich) region of the protein, PCR was used to produce proteins truncated in this region. The primers were designed to introduce a stop codon after a selected amino acid, followed by an EcoRI site to permit cloning (a HindIII site was present on the other primer). The resulting HindIII-EcoRI fragments were cloned into pUCP19. Selection was initially made by colony immunoblotting, selecting for colonies that were reactive with MA7-1. Two mutants, pER158 and pER163, were constructed in this way, but after sequencing it was shown that pER158 contained several unintended sequence rearrangements. The insert in pER163 was fully sequenced to ensure that it was free from errors. No other truncations that expressed fewer than 163 aa and were free from sequence rearrangements could be obtained by this method, which involved screening by colony immunoblotting. However, by screening only for the size of the DNA insert, plasmid pFB154 was constructed successfully by using this PCR method and found to be free of errors. The addition of carbenicillin to growth media was required to maintain pUCP19-based plasmids in P. aeruginosa. However, the resulting bacterial filamentation compromised the later study of cell length. To solve this problem, a 2.0-kb fragment coding for tetracycline resistance from pHP45
-Tc
(11) was inserted into the EcoRI site of selected
plasmids. The control plasmid, pUCP19, with the added tetracycline
resistance cartridge was named pER. The plasmid encoding the entire 326 aa of OprF was named pER326t. Other plasmids had a "t" added to
their names to differentiate them from the initial constructs
(Table 1).
Cell length measurements. Bacteria were grown in high-osmolarity medium with 200 µg of tetracycline per ml to mid-logarithmic phase (75 Klett units) or early logarithmic phase (40 Klett units). A sample was dried on a microscope slide, heat fixed, and stained with crystal violet. For image analysis, cells were viewed by oil immersion with a Zeiss Universal microscope at a magnification of ×100. Images were digitized and analyzed with a SEM-IPS image analysis system (Kronton). For microscopy, cells were viewed at a magnification of ×1,000 by oil immersion, using a Zeiss IIIRS microscope fitted with phase rings and connected to a television monitor. Measurements were performed in a single-blinded fashion by Susan Farmer. At least 100 cells of each strain from three different experiments were measured, and the results were analyzed by Student's t test using the Bonferonni correction.
In vitro growth studies. Strains of P. aeruginosa with wild-type or mutant OprF were assessed for growth in low-osmolarity medium. Overnight cultures grown in high-salt medium were diluted 1:100 into high- and low-salt media, with or without the addition of antibiotics. Cultures were grown in a shaking water bath at 37°C and 160 to 180 rpm. Cell density was determined by using a Klett-Summerson photometer with a green filter.
In vivo growth studies. The in vivo chamber model developed by Day et al. (7) was used for growth of P. aeruginosa in mice. Briefly, a Millipore filter (0.2-µm pore size) was glued on one end of the chamber made from a 1-cm section of a 1-ml plastic syringe barrel. Bacteria resuspended in 0.9% saline at approximately 104 cells per ml, as assessed by total count in a Petroff-Hausser bacteria counter, were added to the chambers, and a second filter was attached to the open end. Four chambers were surgically implanted in the peritoneal cavity of B6D2 F1 mice. The chambers were removed from the mice after 4, 8, 16, 20, 24, or 48 h after implantation and plated for a viable count.
| |
RESULTS |
|---|
|
|
|---|
Confirmation of the structural roles of OprF.
OprF-deficient
strains constructed by chemical mutagenesis have been shown to have a
high frequency of reversion (26) and exhibit phenotypic
variation (16). Phenotypic variation has also been observed
in comparison of OprF-deficient strains insertionally mutagenized by Tn1 mutagenesis or
mutagenesis
(47), though the
-mutagenized strain, named H636,
seemed to contain traits most common to all mutants and most
varied in phenotype from the parent wild type. Due to this observed
phenotypic variation of OprF-deficient strains, and to ensure that the
phenotype associated with H636 was not limited to this mutagenized
strain, another strain was selected for mutagenesis. This strain,
strain M-2, had previously been used in mouse pathogenicity studies
(40) and phagocytosis studies (1, 23, 38, 39).
, was shown by Southern
hybridization to contain only one copy of the
-cartridge insertion in the chromosome, which was located within the oprF
gene (which does not contain a downstream cotranscribed gene
[data not shown]). M2F
was found to have
phenotypes similar to those of the OprF-deficient strain H636: little
to no growth in low-osmolarity medium and a significantly shortened
cell length compared with its parent wild type (see below). This
similarity in phenotypes between the two constructed OprF
strains, H636 and M-2F
, suggests that these are the
true phenotypes associated with OprF deficiency.
OprF-deficient P. aeruginosa has no major growth disadvantage in vivo. Despite the conditional growth defects of OprF-deficient strains, such strains have been observed in clinical situations (6, 31). Therefore, we used a mouse peritoneal chamber model to determine if the OprF-deficient strain H636 had a growth disadvantage in vivo relative to its parent wild-type strain, H103. This model is useful because it permits the growth of more than one strain of bacteria per animal, in separate chambers, thus reducing the animal-to-animal variation. After a lag of 4 h for H103 and between 4 and 8 h for H636, the strains grew with similar doubling times of approximately 40 and 53 min, respectively, reaching stationary phase after about 20 h. These data suggest that OprF-deficient strains do not have a major growth disadvantage in vivo.
Expression of truncated OprF derivatives.
C-terminal
truncation of most
-barrel porins results in destabilization of the
protein, such that little or no protein is observed (8).
We therefore investigated the effect of truncating OprF on
expression of the protein. Selected plasmids encoding full-length or
truncated OprF (described in Materials and Methods) were
electroporated into P. aeruginosa H636, the
OprF-deficient strain. As a control, plasmid pER was electroporated
into the parent wild-type strain, P. aeruginosa
H103. A Western blot of whole-cell lysates of the resulting strains is
shown in Fig. 1A. The antibody used was
MA7-1, which binds to a linear epitope localized to aa 55 to 62 (12). The results showed that the weakened promoter (see
Materials and Methods) allowed good expression of the cloned full-length OprF and of truncated-OprF mutants of 163 aa or larger in
an OprF-deficient strain of P. aeruginosa. The relative
mobility of these proteins corresponded approximately with the number
of amino acids encoded by the plasmid, with specific exceptions: unexpectedly, two bands reactive with MA7-1 were seen with strain H636/pER213t (Fig. 1A, lane 8). One migrated the distance expected for
the 213-aa truncated protein, but the other appeared to have the same
molecular weight as the native protein. In some experiments, H636/pER290t also appeared to have the same molecular weight as the
native protein (Fig. 1A, lane 10). This result suggested either that
suppression of the stop codon in these constructs had occurred or that
oprF sequences on these plasmids were able to recombine into
the chromosome (although it appeared that the plasmid was also retained
in the case of H636/pER213t). This apparent recombination-stop codon
suppression was not always observed with these constructs and was
rarely observed with the other plasmids. However, cultures containing these constructs were monitored closely to ensure that this did not occur during subsequent experiments.
|
background. As mentioned in
Materials and Methods, all plasmids encoding fewer than 163 aa of OprF
(for example, pER158) had significant DNA arrangements if the
constructed plasmid clone was screened for by colony immunoblotting
using antibody MA7-1. This suggested to us that deletion to below 163 aa resulted in an unexpressed, degraded, or lethal protein. To further
study this, plasmid pFB154 was constructed by screening purely for the
correct DNA insert. This plasmid did express in E. coli
DH5
a protein which reacted with antibody MA7-1 and corresponded in
size to the expected 154-aa product. However, the amount of this
product expressed from pFB154 (detected by Western blot analysis of
whole-cell lysates) was markedly reduced, and sometimes undetected, compared with levels of expression normally observed for the
full-length OprF protein or selected truncated OprF products (Fig. 1B).
The cells containing pFB154 grew at a rate comparable to that of cells containing the other plasmids, and pFB154 plasmid DNA extracted from
cells after protein expression was of an amount comparable to that of
extractions of other OprF-expressing plasmids, suggesting that the
reduced amount of protein product from pFB154 was not due to a lethal
effect. A proportion of the product of pFB154 may therefore be
degraded.
In general, these results suggest that approximately 154 to 163 aa of OprF are necessary for production of a stable protein.
Heat and 2-mercaptoethanol modifiability of OprF truncation derivatives. The property of heat modifiability refers to a decrease in the mobility of OprF on SDS-polyacrylamide gel electrophoresis (PAGE) when denatured by boiling in SDS or treatment with TCA. When subjected to such treatments, the recombinant OprF encoded on pER326t and pER290t, and the OprF from the wild-type strain H103, were all normally heat modifiable (Table 2). The truncated versions of OprF encoded on pER163t, pER170-26t, pER188t, and pER215t, however, largely ran with an unaltered mobility, except for a portion of the sample which had an increased mobility when pretreated with TCA or boiled in SDS (Table 2). Such modifiability has been observed with truncated derivatives of OmpA (33). Although the explanation for such behavior is unclear, the results are at least inconsistent with heat-TCA-induced cleavage of the protein, since the change in mobility was similar for all mutant proteins, and no common fragment was observed. The results suggest that a structural rearrangement of OprF was occurring, which may be a reflection of the treatment agents (both TCA and SDS are noted for inducing structure formation in peptides [37, 41, 43]). These results in general indicate that between 215 and 290 aa are required for the protein to be normally heat modifiable.
|
Outer membrane and peptidoglycan association of OprF mutants in P. aeruginosa. Outer membrane preparations were prepared from H103/pER, H636/pER, and H636/pER326t and subjected to SDS-PAGE and Coomassie blue staining. By visual comparison of the samples, it appeared that the cloned OprF was produced at approximately the same levels as the native OprF. Outer membrane preparations were also obtained from cultures of H636 expressing selected truncated OprF proteins (encoded on plasmids pER290t, pER215t, pER188t, pER170-26t, and pER163t). According to a Western blot of these samples probed with antibody MA7-1, all truncated and full-length OprF proteins were associated with the outer membrane. This result suggests that the N-terminal 163 aa of OprF are sufficient for outer membrane association in P. aeruginosa.
OprF has been shown to be noncovalently associated with the peptidoglycan in strain H103 (17). To determine the regions of OprF involved in peptidoglycan association, Triton-EDTA- and Triton-lysozyme-soluble fractions of outer membrane preparations were prepared (18). The Triton-EDTA-soluble fraction contains proteins that are stabilized in the outer membrane by lipopolysaccharide association with divalent cations like MgCl2. Incubation of the Triton-EDTA-insoluble fraction with lysozyme releases outer membrane proteins that are strongly associated with the peptidoglycan. Full-length OprF from H103/pER and H636/pER326t was found primarily in the Triton-lysozyme-soluble fraction (Fig. 2, lanes 3 and 5). Only a small amount was observed in the Triton-EDTA fraction (Fig. 2, lanes 2 and 4) or the pellet remaining after Triton-lysozyme treatment. All of the truncated proteins tested (encoded on plasmids pER163t, pER170-26t, pER188t, and pER215t) were located in the Triton-EDTA-soluble fraction (Fig. 2, lanes 6, 8, 11, and 13), indicating that they were not strongly associated with the peptidoglycan. These data suggest that more than 215 aa of OprF are required for strong association with the peptidoglycan and confirm that, like the native OprF, the recombinant OprF is peptidoglycan associated.
|
Binding of OprF-specific monoclonal antibodies to the truncated OprF mutants. A series of OprF-specific monoclonal antibodies have been mapped to specific regions or linear epitopes of OprF (12, 23) and were used here for the analysis of the truncated-OprF mutants by colony and Western blot methods. As controls, the strains H636/pER326t and H103/pER were shown to bind all of the monoclonal antibodies tested, while the negative control strain, H636/pER, did not bind any of the antibodies. All of the truncated-OprF mutants studied (containing plasmids pER290t, pER215t, pER188t, pER170-26t, and pER163t) expressed truncated protein which was stable in P. aeruginosa, as shown by their ability to bind antibody MA7-1. Strains H636/pER163t and H636/pER188t did not bind any other antibodies, including MA7-8 and MA4-4, which recognize epitopes that require intact disulfide bonds and have been previously localized between aa 152 and 210 (12). This finding suggests that part or all of these epitopes lie downstream of aa 188 or that the cysteines present in the H636/pER188t product do not form the correct disulfide bond conformation. H636/pER215t bound both MA7-8 and MA4-4, indicating that this truncated protein was not degraded and that the disulfide bond region of this protein had assumed the wild-type conformation. As expected, strain H636/pER290t bound all of the antibodies tested except antibody MA5-8, which binds between amino acid residues 305 and 312 (12). Since seven of the monoclonal antibodies tested recognize conformational epitopes, this finding suggests that the truncated protein folds normally.
Growth of P. aeruginosa expressing truncated OprF derivatives. OprF is required for the growth of P. aeruginosa in low-osmolarity media (references 16, 26, and 47 and this work). To determine if the entire OprF protein was required for growth under these conditions, the truncated OprF mutants were grown in high- and low-osmolarity media.
In the initial growth studies, the addition of tetracycline to ensure plasmid maintenance appeared to inhibit the growth of the controls. Since the outer membrane of P. aeruginosa is stabilized by divalent cations, and since tetracycline can act as a divalent-cation chelator (28), MgCl2 was added to the growth media. Figure 3 shows an example of the growth of the truncated OprF strains in low- and high-osmolarity media with the addition of 5 mM MgCl2 and 200 µg of tetracycline per ml. All of the strains tested were able to grow at approximately the same rate in the high-salt medium. In the low-salt medium, H636/pER326t grew at the same rate as the wild-type strain and the OprF-deficient strain H636/pER showed little or no growth during the 7 h tested. In this low-salt medium, the strains with truncated OprF grew at a rate similar to, or slightly less than, the rate for the wild-type strain for about the first 4 h. This initial growth rate lasted from 0 to 4 h in independent experiments. This initial ability to grow at a rate near that of the wild-type strain may have reflected a requirement for adaptation to the low-osmolarity medium. After this initial phase, the remaining strains appeared to fall into two groups. H636/pER290t and H636/pER215t had growth rates less than those of the strains expressing full-length OprF but greater than those of the other strains, with the rate for H636/pER290t being greater than that for strain H636/pER215t. Strains H636/pER163t, H636/pER170-26t, and H636/pER188t always grew at a rate higher than that of the OprF-deficient strain, H636/pER, but lower than that of H636/pER290t or H636/pER215t. Although the growth rate of strain H636/pER163t was higher than those of H636/pER188t and H636/pER170-26t in the experiment presented in Fig. 3, this was not the case in all experiments. One common feature which could differentiate these two groups of strains was that H636/pER290t and H636/pER215t contain a properly folded cysteine disulfide bond region (this work), while H636/pER163t, H636/pER170-26t, and H636/pER188t do not.
|
Length of P. aeruginosa cells expressing
truncated OprF.
Previous studies have shown that
OprF-deficient strains are significantly shorter than their wild-type
parent strains, as judged by image analysis (47) and by
electron microscopy (16). In this study, cells were grown
with 200 µg of tetracycline per ml in LBHS to mid-log phase (50 Klett
units), fixed, stained, and measured in a blinded fashion directly from
a video monitor connected to a phase-contrast microscope. All of the
cells had similar widths but varied in length. Results from one of
these experiments are shown in Table 3.
The OprF-deficient strain, H636/pER, was 61% of the length of its
parent strain, H103/pER. Consistent with this, the newly constructed
OprF-deficient strain, M-2F
, was about 70% of the length
of the parent strain, M-2. Strain H636 containing plasmid pER163t,
pER188t, pER170-26t, pER215t, pER290t, or pER326t was an average of 77, 85, 86, 88, 91 or 97%, respectively, the length of H103/pER. All of
the strains expressing truncated OprF were significantly larger than
the OprF-deficient strain H636/pER (P
0.05 in this
case and all subsequent comparisons). There was no significant
difference between the wild-type strain H103/pER and the
strain expressing recombinant full-length OprF, H636/pER326t. There was
also no significant difference between H636/pER290t and H636/pER326t.
None of the truncated OprF mutants were significantly different from
one another, with the exception of H636/pER163t. H636/pER163t appeared
to be intermediate in size between OprF-deficient H636/pER and H636
expressing recombinant full-length OprF and was significantly different
from both of them. These results indicate that the cloned full-length
OprF was able to complement the size defect in the OprF-deficient
strain, H636. While truncating OprF did appear to reduce cell length, the cells were never as short as those of the OprF-deficient strain.
|
| |
DISCUSSION |
|---|
|
|
|---|
Our results provide some important confirmation of theories
regarding OprF structure and function. We have demonstrated that residues in the C-terminal domain of OprF are required for strong peptidoglycan association, as previously proposed (9).
Expression of our truncated OprF mutants in E. coli or
P. aeruginosa suggests that the first 154 to 163 aa of
OprF are needed to produce a stable protein. This possibility is in
strong agreement with the proposal that the first 160 aa of OprF form
a
-barrel structure and suggests that residues critical
to proper conformation of this domain are present between aa 154 and 163. The residues between aa 150 and 160 conform to the consensus
sequence of the 16th C-terminal
strand of the porin superfamily
(21, 22). Studies of other porins, such as E. coli PhoE, suggest that a phenylalanine residue in this terminal
strand (equivalent to OprF residue 160) is critical for protein
stability and proper folding (8). Our results may thus
reflect deletion of such a critical residue. The minimum number of
residues required for stable OprF expression correlated with
the number required for the expression of OmpA in E. coli (4), even though there is no sequence similarity
between OprF and OmpA in this N-terminal region. However, there is
growing evidence that porins can adopt a similar
-barrel structure
despite having virtually no sequence similarity with one another
(35).
Insight into the role of OprF in cell structure and the effect of OprF
deficiency was gained through studies of the length and growth in vitro
of P. aeruginosa strains expressing truncated OprF
derivatives. While all of the truncated OprF mutants examined grew
significantly better than the OprF-deficient mutant in a low-osmolarity
environment, it seemed that wild-type-length OprF was required for
wild-type growth. Likewise for cell length, all of the truncated OprF
mutant cells were significantly longer than those of the OprF-deficient
mutant, though almost wild-type-length OprF was required for
full-length cells. There seemed to be some gradation in both of these
properties, with the strain expressing the 163-aa OprF truncation
supporting an intermediate growth rate in low-osmolarity medium and
intermediate cell length relative to full-length OprF and
OprF-deficient strains. Overall, the results suggest that the
N-terminal domain of OprF (present in all truncated OprF mutants
studied), as well as the C-terminal domain, plays a role in the
maintenance of both wild-type cell length and growth in low-osmolarity
medium. This has some notable implications; for example, it suggests
that the loss of strong association between the peptidoglycan and the
outer membrane-anchored OprF protein is not the sole
explanation for the change in cell shape observed in
OprF-deficient P. aeruginosa (as has been previously
alluded to [9, 48]). In fact, our cell length studies
suggest that loss of strong peptidoglycan association was no more
influential than loss of the N terminus of OprF. For example, the
change in cell length between the strain expressing full-length
recombinant OprF and the 215-aa truncation (which does not bind to
peptidoglycan) is less than the change in cell length between the
OprF-deficient strain and cells expressing the 163-aa truncation
(which contains the whole proposed
-barrel region). It should
be noted that the available methods for assessing peptidoglycan
association reveal only strong associations, and so it cannot be
discounted that the results are a reflection of a gradually weakening
peptidoglycan association as OprF is truncated. However, all of these
results seem to reflect a general destabilization of the outer membrane due to truncation or deficiency of OprF, in which both the N terminus and the C terminus cooperatively play a role. The N terminus may act as
an additional membrane anchor for the C-terminal regions of the protein
which bind peptidoglycan. Possible cooperativity between OprF and other
peptidoglycan-associated proteins such as OprL and OprI also needs to
be investigated.
While OprF deficiency seems to place a significant degree of stress on the cell, our mouse model studies suggest that P. aeruginosa is not adversely affected by an OprF deficiency during growth in vivo. It is possible that P. aeruginosa requires OprF solely for growth and survival in low-osmolarity niches such as water and that the lack of OprF actually confers an advantage to the cell when confronting a barrage of antibiotics and host defenses during human infection. Its function as a porin has led to the proposal that OprF deficiency plays a role in the resistance of P. aeruginosa to antimicrobial therapy in vivo (20). Moreover, OprF deficiency may also be of advantage to P. aeruginosa when infecting humans, since OprF has been shown to function as a significant antigen (13, 19). It might therefore be to the bacterium's benefit to rid itself of this protein in order to evade the host's immune response. We suspect that both of these issues might play a role in explaining the occurrence of OprF deficiency in clinical isolates of P. aeruginosa.
| |
ACKNOWLEDGMENTS |
|---|
We thank Susan Farmer (Department of Microbiology and Immunology, UBC) for assistance with cell length measurement experiments.
This work was financially supported by the Canadian Cystic Fibrosis Foundation (CCFF) and the Medical Research Council of Canada. E.G.R. and F.S.L.B. were the recipients of a CCFF studentship and CCFF fellowship, respectively.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Microbiology and Immunology, University of British Columbia, Vancouver, British Columbia, Canada V6T 1W5. Phone: (604) 822-2682. Fax: (604) 822-6041. E-mail: bob{at}cmdr.ubc.ca.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Battershill, J.,
D. P. Speert, and R. E. W. Hancock.
1987.
Use of monoclonal antibodies against protein F of Pseudomonas aeruginosa as opsonins for phagocytosis by macrophages.
Infect. Immun.
55:2531-2533 |
| 2. |
Birnboim, H. C., and J. Doly.
1979.
A rapid alkaline extraction procedure for screening recombinant plasmid DNA.
Nucleic Acids Res.
7:1513-1523 |
| 3. |
Blackwood, L. L., and J. E. Pennington.
1981.
Influence of mucoid coating on clearance of Pseudomonas aeruginosa.
Infect. Immun.
32:443-448 |
| 4. | Bremer, E., S. T. Cole, I. Hindennach, U. Henning, E. Beck, C. Kurz, and H. Schaller. 1982. Export of a protein into the outer membrane of Escherichia coli K12: stable incorporation of the OmpA protein requires less than 193 amino-terminal amino-acids residues. Eur. J. Biochem. 122:223-231[Medline]. |
| 5. | Bryan, L. E. 1979. Resistance to antimicrobial agents: the general nature of the problem and the basis of resistance, p. 219-270. In R. Doggett (ed.), Pseudomonas aeruginosa: clinical manifestations of infection and current therapy. Academic Press, New York, N.Y. |
| 6. |
Chamberland, S.,
F. Malouin,
H. R. Rabin,
T. Schollaardt,
T. R. Parr, Jr., and L. E. Bryan.
1990.
Persistence of Pseudomonas aeruginosa during ciprofloxacin therapy of a cystic fibrosis patient: transient resistance to quinolones and protein F-deficiency.
J. Antimicrob. Chem.
25:995-1010 |
| 7. | Day, S. E. J., K. K. Vasil, R. J. Russel, and J. P. Arbuthnott. 1980. A simple method for the study in vivo of bacteria growth and accompanying host response. J. Infect. Dis. 2:39-51. |
| 8. | de Cock, H., M. Struyvé, M. Kleerebesem, T. van der Krift, and J. Tommassen. 1997. Role of the carboxy-terminal phenylalanine in the biogenesis of outer membrane protein PhoE of Escherichia coli K-12. J. Mol. Biol. 269:473-478[Medline]. |
| 9. | De Mot, R., and J. Vanderleyden. 1994. MicroCorrespondence. Mol. Microbiol. 13:379-380[Medline]. |
| 10. | Farinha, M. A., and A. M. Kropinski. 1990. High efficiency electroporation of Pseudomonas aeruginosa using frozen cell suspensions. FEMS Microbiol. Lett. 70:221-226. |
| 11. | Fellay, R., J. Frey, and H. Krisch. 1987. Interposon mutagenesis of soil and water bacteria: a family of DNA fragments designed for in vitro insertional mutagenesis of Gram-negative bacteria. Gene 52:147-154[Medline]. |
| 12. |
Finnen, R. L.,
N. L. Martin,
R. J. Siehnel,
W. A. Woodruff,
M. Rosok, and R. E. W. Hancock.
1992.
Analysis of the major outer membrane protein OprF from Pseudomonas aeruginosa using truncated derivatives and monoclonal antibodies.
J. Bacteriol.
174:4977-4985 |
| 13. |
Gilleland, H. E., Jr.,
M. G. Parker,
J. M. Matthews, and R. D. Berg.
1984.
Use of a purified outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine in mice.
Infect. Immun.
44:49-54 |
| 14. |
Goldberg, J. B., and D. E. Ohman.
1984.
Cloning and expression in Pseudomonas aeruginosa of a gene involved in the production of alginate.
J. Bacteriol.
158:1115-1121 |
| 15. | Gotoh, N., H. Wakebe, and T. Nishino. 1989. Ultrastructural aspects of fragility of Pseudomonas aeruginosa outer membrane devoid of protein F. FEMS Microbiol. Lett. 59:51-54. |
| 16. |
Gotoh, N.,
H. Wakebe, and E. Yoshihara.
1989.
Role of protein F in maintaining structural integrity of the Pseudomonas aeruginosa outer membrane.
J. Bacteriol.
171:983-990 |
| 17. |
Hancock, R. E. W., and A. M. Carey.
1979.
Outer membrane of Pseudomonas aeruginosa: heat- and 2-mercaptoethanol-modifiable proteins.
J. Bacteriol.
140:902-910 |
| 18. |
Hancock, R. E. W.,
R. T. Irwin,
J. W. Costerton, and A. M. Carey.
1981.
The outer membrane of Pseudomonas aeruginosa: peptidoglycan associated proteins.
J. Bacteriol.
145:628-631 |
| 19. | Hancock, R. E. W., L. M. Mutharia, and E. C. A. Mouat. 1985. Immunotherapeutic potential of monoclonal antibodies against Pseudomonas aeruginosa protein F. Eur. J. Clin. Microbiol. 4:224-227[Medline]. |
| 20. | Hancock, R. E. W., R. Siehnel, and N. Martin. 1990. Outer membrane proteins of Pseudomonas. Mol. Microbiol. 4:1069-1075[Medline]. |
| 21. | Jeanteur, D., J. H. Lakey, and F. Pattus. 1991. The bacterial porin superfamily: sequence alignment and structure prediction. Mol. Microbiol. 5:2153-2164[Medline]. |
| 22. | Jeanteur, D., J. H. Lakey, and F. Pattus. 1994. The porin superfamily: diversity and common features, p. 363-380. In J.-M. Ghuysen, and R. Hakenbeck (ed.), Bacterial cell wall. Elsevier, Amsterdam, The Netherlands. |
| 23. | Martin, N. L., E. G. Rawling, R. S. Y. Wong, M. Rosok, and R. E. W. Hancock. 1993. Conservation of surface epitopes in Pseudomonas aeruginosa outer membrane porin protein OprF. FEMS Microbiol. Lett. 113:261-266[Medline]. |
| 24. |
Mutharia, L. M., and R. E. W. Hancock.
1983.
Surface localization of Pseudomonas aeruginosa outer membrane porin protein using monoclonal antibodies.
Infect. Immun.
42:1027-1033 |
| 25. | Mutharia, L. M., and R. E. W. Hancock. 1985. Characterization of two surface-localized antigenic sites on porin protein F of Pseudomonas aeruginosa. Can. J. Microbiol. 31:381-390[Medline]. |
| 26. |
Nicas, T. I., and R. E. W. Hancock.
1983.
Pseudomonas aeruginosa outer membrane permeability: isolation of a porin F-deficient mutant.
J. Bacteriol.
153:281-285 |
| 27. |
Nikaido, H.
1994.
Prevention of drug access to bacterial targets: permeability barriers and active efflux.
Science
264:382-387 |
| 28. |
Nikaido, H., and D. G. Thanassi.
1993.
Penetration of lipophilic agents with multiple protonation sites into bacterial cells: tetracyclines and fluoroquinolones as examples.
Antimicrob. Agents Chemother.
37:1393-1399 |
| 29. |
Pennington, J. E.,
G. E. Small,
M. E. Lostrom, and G. B. Pier.
1986.
Polyclonal and monoclonal antibody therapy for exponential Pseudomonas aeruginosa pneumonia.
Infect. Immun.
54:239-244 |
| 30. | Peterson, G. L. 1977. A simplification of the protein assay method of Lowry et al. which is more generally acceptable. Anal. Biochem. 83:346-356[Medline]. |
| 31. |
Piddock, L. J. V.,
M. C. Hall,
F. Bellido,
M. Bains, and R. E. W. Hancock.
1992.
A pleiotropic, posttherapy, enoxacin-resistant mutant of Pseudomonas aeruginosa.
Antimicrob. Agents Chemother.
36:1057-1061 |
| 32. | Rawling, E. G., N. L. Martin, and R. E. W. Hancock. 1995. Epitope mapping of the Pseudomonas aeruginosa major outer membrane porin protein OprF. Infect. Immun. 63:38-42[Abstract]. |
| 33. | Ried, G., R. Koebnik, I. Hindennach, B. Mutschler, and U. Henning. 1994. Membrane topology and assembly of the outer membrane protein OmpA of Escherichia coli K12. Mol. Gen. Genet. 243:127-135[Medline]. |
| 34. | Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. |
| 35. | Schulz, G. E. 1993. Bacterial porins: structure and function. Curr. Opin. Cell Biol. 5:701-707[Medline]. |
| 36. | Schweizer, H. P. 1991. Escherichia-Pseudomonas shuttle vectors derived from pUC18/19. Gene 97:109-112[Medline]. |
| 37. | Sivaraman, T., T. K. S. Kumar, G. Jayaraman, C. C. Han, and C. Yu. 1997. Characterization of a partially structured state in an all-beta-sheet protein. Biochem. J. 321:457-464. |
| 38. | Speert, D. P., M. Bond, R. C. Woodman, and J. T. Curnutte. 1994. Infection with Pseudomonas cepacia in chronic granulomatous disease: role of nonoxidative killing by neutrophils in host defense. J. Infect. Dis. 170:1524-1531[Medline]. |
| 39. |
Speert, D. P., and L. Thorson.
1991.
Suppression by human recombinant gamma interferon of in vitro macrophage nonopsonic and opsonic phagocytosis and killing.
Infect. Immun.
59:1893-1898 |
| 40. | Stieritz, D. D., and I. A. Holder. 1975. Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: description of a burned mouse model. Infect. Immun. 131:688-691. |
| 41. | Takenaka, O., A. Takenaka, and Y. Inada. 1976. Sodium trichloroacetate-induced helical conformation of poly(L-lysine). Biochim. Biophys. Acta 439:302-309[Medline]. |
| 42. | Vogel, H., and F. Jahnig. 1986. Models for the structure of outer-membrane proteins of Escherichia coli derived from Raman spectroscopy and prediction methods. J. Mol. Biol. 190:191-199[Medline]. |
| 43. | Waterhous, D. V., and W. C. Johnson. 1994. The importance of environment in determining secondary structure in protein. Biochemistry 33:212-218. |
| 43a. | Wong, R. Unpublished data. |
| 44. | Wong, R. S. Y., H. Jost, and R. E. W. Hancock. 1993. Linker-insertion mutagenesis of Pseudomonas aeruginosa outer membrane protein OprF. Mol. Microbiol. 10:283-292[Medline]. |
| 45. | Wong, R. S. Y., R. A. Wirtz, and R. E. W. Hancock. 1995. Pseudomonas aeruginosa outer membrane protein OprF as an expression vector for foreign epitopes: the effects of positioning and length on the antigenicity of the epitope. Gene 158:55-60[Medline]. |
| 46. |
Woodruff, W. A.,
T. R. Parr, Jr.,
R. E. W. Hancock,
L. F. Hanne,
T. I. Nicas, and B. H. Iglewski.
1986.
Expression in Escherichia coli and function of Pseudomonas aeruginosa outer membrane porin protein F.
J. Bacteriol.
167:473-479 |
| 47. |
Woodruff, W. A., and R. E. W. Hancock.
1988.
Construction and characterization of Pseudomonas aeruginosa porin protein F-deficient mutants after in vivo and in vitro mutagenesis of the cloned protein F gene in Escherichia coli.
J. Bacteriol.
170:2592-2598 |
| 48. |
Woodruff, W. A., and R. E. W. Hancock.
1989.
Pseudomonas aeruginosa outer membrane protein F: structural role and relationship to the Escherichia coli OmpA protein.
J. Bacteriol.
171:3304-3309 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Appl. Environ. Microbiol. | Infect. Immun. | Eukaryot. Cell |
|---|---|---|
| Mol. Cell. Biol. | J. Virol. | Microbiol. Mol. Biol. Rev. |
| ALL ASM JOURNALS |